Last reviewed · How we verify
SRN001
At a glance
| Generic name | SRN001 |
|---|---|
| Sponsor | siRNAgen Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males (PHASE1)
- The First-in-human Study of SRN-001 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SRN001 CI brief — competitive landscape report
- SRN001 updates RSS · CI watch RSS
- siRNAgen Therapeutics Inc. portfolio CI